Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
… We completed a randomised phase 3 trial to assess the role of preoperative radiotherapy
after induction chemotherapy in patients with IIIA/N2 non-small-cell lung cancer. The addition …
after induction chemotherapy in patients with IIIA/N2 non-small-cell lung cancer. The addition …
Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results
I Oze, K Hotta, K Kiura, N Ochi, N Takigawa… - PloS one, 2009 - journals.plos.org
… lung cancer (NSCLC) enrolled in phase III trials. The analysis similarly revealed a very small
increase in patient survival (3.61 days per year) but one that was statistically significant in …
increase in patient survival (3.61 days per year) but one that was statistically significant in …
Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress
… Phase III Trials The phase III trials initiated for patients with extensive-stage SCLC were
identified through a search of the National Cancer Institute Cancer Therapy Evaluation Program …
identified through a search of the National Cancer Institute Cancer Therapy Evaluation Program …
Twenty-two years of phase III trials for patients with advanced non–small-cell lung cancer: Sobering results
OS Breathnach, B Freidlin, B Conley… - Journal of Clinical …, 2001 - ascopubs.org
… Prior analysis of phase III trials for patients with extensive-stage small-cell lung cancer (SCLC)
revealed that the median of median survival of patients treated on phase III trials and of …
revealed that the median of median survival of patients treated on phase III trials and of …
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - ascopubs.org
… erlotinib came from phase I/II studies in previously treated patients. In one phase II trial in
NSCLC, … In a large phase III trial in previously treated patients with advanced NSCLC, erlotinib …
NSCLC, … In a large phase III trial in previously treated patients with advanced NSCLC, erlotinib …
Phase III study of matrix metalloproteinase inhibitor prinomastat in non–small-cell lung cancer
D Bissett, KJ O'Byrne, J Von Pawel… - Journal of Clinical …, 2005 - ascopubs.org
… Study results at an interim analysis and lack of efficacy in another phase III trial prompted
early closure of this study. … had stage IIIB disease with T4 primary tumor, 193 had stage IV …
early closure of this study. … had stage IIIB disease with T4 primary tumor, 193 had stage IV …
Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018
ML Reale, E De Luca, P Lombardi, L Marandino… - Lung Cancer, 2020 - Elsevier
… Aim of this systematic review is to describe QoL adoption and reporting in randomized phase
III trials testing anticancer drugs in lung cancer patients, published between 2012 and 2018 …
III trials testing anticancer drugs in lung cancer patients, published between 2012 and 2018 …
Phase II study of imatinib in patients with small cell lung cancer
BE Johnson, T Fischer, B Fischer, D Dunlop… - … cancer research, 2003 - AACR
… untreated extensive-stage SCLC were included because prior studies have shown higher
… with untreated extensive-stage SCLC, we used a “windowed” Phase II study design, with …
… with untreated extensive-stage SCLC, we used a “windowed” Phase II study design, with …
Sequential vs concurrent chemoradiation for stage III non–small cell lung cancer: randomized phase III trial RTOG 9410
WJ Curran Jr, R Paulus, CJ Langer… - … the National Cancer …, 2011 - academic.oup.com
… Study design In a randomized phase III trial, 610 patients with inoperable stage II or III
non–small cell lung cancer were randomly assigned to two different concurrent regimens (…
non–small cell lung cancer were randomly assigned to two different concurrent regimens (…
Phase III study of second-line chemotherapy for advanced non–small-cell lung cancer with weekly compared with 3-weekly docetaxel
W Schuette, S Nagel, T Blankenburg… - Journal of Clinical …, 2005 - ascopubs.org
… We found that the toxicity rates for 3-weekly docetaxel 75 mg/m 2 were generally … phase III
studies, 5,6 although grade 3 to 4 neutropenia was considerably less frequent in our study (21…
studies, 5,6 although grade 3 to 4 neutropenia was considerably less frequent in our study (21…
相关搜索
- randomized phase iii trial lung cancer
- cell lung cancer phase iii trial
- systematic review phase iii trials
- multicentre phase ii trial lung cancer
- southwest oncology group phase ii study
- weekly docetaxel randomized phase iii study
- defined duration phase iii trial
- erlotinib in combination phase iii study
- phase 3 study induction treatment
- multicentre phase ii trial selected patients
- randomized phase iii trial vincristine regimen
- assessment and reporting phase iii trials
- life analysis phase iii trials
- phase 3 study surgery in patients
- phase 3 study concurrent chemoradiotherapy
- multicentre phase ii trial neoadjuvant chemotherapy